Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation
- PMID: 26306985
- DOI: 10.1007/s00404-015-3865-0
Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation
Abstract
Objective: Primary neuroendocrine tumors in the ovary are rare. These tumors arise from the neuroendocrine cell system of ovarian stroma and surface epithelium, and may also arise from teratoma. We present four primary ovarian neuroendocrine tumors and compare clinicopathologic findings based on tumor histogenesis and site of origin.
Design: Four primary ovarian neuroendocrine tumors were identified from our 10-year departmental archives. H&E slides and immunostains were reviewed and the diagnoses were confirmed. Clinical history, imaging studies, and follow-up data were obtained from medical records.
Results: Patients' ages ranged from 26 to 63. All patients presented with abdominal discomfort and unilateral or bilateral ovarian masses. MRI and CT scans from cases 1 and 2 revealed a solid ovarian mass with no extra-ovarian extension. In case 1, the patient also had a cystic mass in the opposite ovary and an elevated urine 5-HIAA. Microscopically, case 1 revealed a well-differentiated carcinoid tumor with no surface epithelial involvement, and a mature teratoma in the contralateral ovary. Case 2 revealed a stromal carcinoid within the ovarian parenchyma. Imaging studies from cases 3 and 4 showed large complex masses with peritoneal implants and ascites. In both cases 3 and 4, tumor grossly involved both ovarian parenchyma and surface epithelium with multiple pelvic implants. In addition, liver metastases were present in case 4. Microscopically, these tumors were poorly differentiated carcinoma with neuroendocrine differentiation. Histologic sections revealed extensive necrosis, and both cases showed positivity for neuroendocrine markers.
Conclusions: Primary neuroendocrine tumors in the ovary are rare and consist of a group of heterogeneous malignancies that express similar immunohistochemical markers. Primary neuroendocrine tumors that are limited to the ovarian parenchyma often arise from ovarian stroma and teratoma, and are carcinoid tumors with a good prognosis. Neuroendocrine tumors that arise from surface epithelium or dedifferentiate from de novo carcinoma often involve both ovarian stroma and surface epithelium and clinically present as aggressive malignancies with poor prognoses.
Keywords: Carcinoid; Carcinoma; Neuroendocrine tumor; Ovary.
Similar articles
-
Primary neuroendocrine tumors of ovary: A clinicopathological spectrum in a tertiary care hospital with review of literature.J Cancer Res Ther. 2023 Jan 1;19(Suppl 2):S623-S627. doi: 10.4103/jcrt.jcrt_28_22. Epub 2023 Apr 29. J Cancer Res Ther. 2023. PMID: 38384029 Review.
-
Ovarian mucinous carcinoids including some with a carcinomatous component: a report of 17 cases.Am J Surg Pathol. 2001 May;25(5):557-68. doi: 10.1097/00000478-200105000-00001. Am J Surg Pathol. 2001. PMID: 11342766
-
Primary adenocarcinoid tumor of the ovary arising in mature cystic teratoma. A case report.Eur J Gynaecol Oncol. 2009;30(1):110-2. Eur J Gynaecol Oncol. 2009. PMID: 19317273
-
Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases.Am J Surg Pathol. 2007 May;31(5):774-82. doi: 10.1097/01.pas.0000213422.53750.d1. Am J Surg Pathol. 2007. PMID: 17460463
-
Synchronous colonic adenocarcinoma and well-differentiated neuroendocrine tumor arising in a mature cystic teratoma of ovary - rare presentation in a postmenopausal woman with literature review.Indian J Pathol Microbiol. 2021 Apr-Jun;64(2):385-389. doi: 10.4103/IJPM.IJPM_41_20. Indian J Pathol Microbiol. 2021. PMID: 33851642 Review.
Cited by
-
Case series of ovarian neuroendocrine carcinoma: overview of clinicopathological features.BMC Womens Health. 2023 Nov 13;23(1):595. doi: 10.1186/s12905-023-02722-4. BMC Womens Health. 2023. PMID: 37953251 Free PMC article.
-
Primary neuroendocrine tumors of the ovary: Management and outcomes.Cancer Med. 2021 Dec;10(23):8558-8569. doi: 10.1002/cam4.4368. Epub 2021 Nov 12. Cancer Med. 2021. PMID: 34773393 Free PMC article.
-
Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden.J Immunother Cancer. 2017 Sep 19;5(1):75. doi: 10.1186/s40425-017-0281-y. J Immunother Cancer. 2017. PMID: 28923100 Free PMC article.
-
Metastatic Primary Neuroendocrine Tumor of Ovary-A Rare Presentation.Indian J Radiol Imaging. 2022 Jun 23;32(2):270-274. doi: 10.1055/s-0042-1744233. eCollection 2022 Jun. Indian J Radiol Imaging. 2022. PMID: 35924124 Free PMC article.
-
Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.Endocr Pathol. 2019 Mar;30(1):35-42. doi: 10.1007/s12022-018-9559-y. Endocr Pathol. 2019. PMID: 30523500
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical